GenoME's Key Milestones To Date
Episode 25, Nov 14, 2022, 09:52 AM
Shannon Beattie (Chief Executive Officer of GenoME Diagnostics Ltd) joins the Deepbridge Discovery Podcast to discuss how GenoME came to be, her background, the key milestones to date for GenoME and the next steps and goals for GenoME in the future.
About GenoME Diagnostics Ltd:
GenoME Diagnostics is a new spinout from the prestigious Patrick G Johnston Centre for Cancer Research at Queen’s University Belfast. They are developing a novel blood test for earlier and more accurate diagnosis of ovarian cancer and to improve upon the accuracy of the current gold standard ovarian cancer diagnostic test known as CA125; a test which is fraught with many inaccuracies. GenoME Diagnostics aims to reduce the misdiagnosis and late diagnosis associated with CA125 to improve patient survival and outcome.
GenoME's pipeline could be applied to biomarker discovery and development in a wide range of diseases and applications, which they plan to pursue, both in-house and for external parties.
- - -
Supporting growth-focused companies and entrepreneurs has never been more important, but it is important to understand the people and ideas behind such investment opportunities.
Join the Deepbridge Capital team each week as they discuss all things Deepbridge, speak with various investment experts within the company and discover more about the founders and CEOs’ running the portfolio companies Deepbridge invests in. Each episode contains an informal conversation to understand how these leaders and teams perform in order to achieve their goals. Investments in early-stage companies are illiquid and high risk – investors could lose all of their capital.
About GenoME Diagnostics Ltd:
GenoME Diagnostics is a new spinout from the prestigious Patrick G Johnston Centre for Cancer Research at Queen’s University Belfast. They are developing a novel blood test for earlier and more accurate diagnosis of ovarian cancer and to improve upon the accuracy of the current gold standard ovarian cancer diagnostic test known as CA125; a test which is fraught with many inaccuracies. GenoME Diagnostics aims to reduce the misdiagnosis and late diagnosis associated with CA125 to improve patient survival and outcome.
GenoME's pipeline could be applied to biomarker discovery and development in a wide range of diseases and applications, which they plan to pursue, both in-house and for external parties.
- - -
Supporting growth-focused companies and entrepreneurs has never been more important, but it is important to understand the people and ideas behind such investment opportunities.
Join the Deepbridge Capital team each week as they discuss all things Deepbridge, speak with various investment experts within the company and discover more about the founders and CEOs’ running the portfolio companies Deepbridge invests in. Each episode contains an informal conversation to understand how these leaders and teams perform in order to achieve their goals. Investments in early-stage companies are illiquid and high risk – investors could lose all of their capital.